Case Study
EMMAC Life Sciences Group brings together cutting-edge scientific research with the latest innovations in medical cannabis cultivation, extraction and production.
Investment performance
SEED first invested in European medical cannabis company EMMAC in March 2019 to the tune of £2m.
Between 2019-2021, we provided financial and advisory support to its team including the participation in a Convertible Loan Note (‘CLN’) at a cash cost of £750k. In April 2021, we sold our entire interest to Curaleaf Holdings Inc., a leading medical and wellness cannabis operator in the US, for c. £5m cash recording a profit on the sale of approximately £1.9m, to deliver an overall return of 1.86 times our original investment. The proceeds of this sale were then used to make further investments in accordance with our investing policy.
